Sciwind Biosciences is a Chinese clinical-stage biopharmaceutical company developing long-acting peptide therapeutics for metabolic disease, with a lead asset in obesity based on a once-monthly GLP-1/glucagon dual agonist formulation. The company has signed two Western licensing deals for its obesity candidate and is open to additional geographic partnerships as it seeks to expand beyond the Chinese market.
Company Info
Funding & Investor Relations
None publicly disclosed; Chinese biotech focused on partnerships and domestic commercial development.
Upcoming Milestones & Key Dates
Phase 2 SW-EX-01 interim data in Chinese obesity cohort
Expected additional Western licensing or co-development deal
Clinical Development Pipeline
Recent News
Chinese peptide developer Sciwind Biosciences is actively shopping additional Western licensing deals for its once-monthly obesity candidate after signing two partners in the past 12 months, founder and CEO Nick Yang told Endpoints.
Chinese biotech Sciwind Biosciences has signed licensing deals with two Western partners for its obesity peptide candidate, but the company is signaling openness to additional global deals as it pursues broader geographic reach for the asset.
Leadership Team
Founder and Chief Executive Officer
Chief Medical Officer
Chief Scientific Officer
Careers & Job Openings